Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.53 |
| ▸ | VCP | P55072 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24041228 | 0.91 | CD274 (0.51) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL30477887 | 0.88 | CD274 (0.53) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL19640745 | 0.88 | CD274 (0.53) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL19640691 | 0.88 | CD274 (0.53) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL19640690 | 0.88 | CD274 (0.53) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL19640613 | 0.88 | PDCD1 (0.55) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL30477888 | 0.88 | PDCD1 (0.55) | CD274PDCD1VCPHTR7HTR1A | |
| SCHEMBL19640628 | 0.86 | CD274 (0.56) | CD274PDCD1VCPMAPT | |
| SCHEMBL30477890 | 0.86 | CD274 (0.56) | CD274PDCD1VCPMAPT | |
| SCHEMBL19640659 | 0.85 | CD274 (0.53) | CD274PDCD1VCPHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | claimed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | claimed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885VCP 3426/4885 |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885VCP 3426/4885 |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885VCP 3426/4885 |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885VCP 3426/4885 |
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | KRAS, RASSF5, RASSF2 | CD274 4257/4885PDCD1 1369/4885VCP 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.